Le Lézard
Classified in: Health
Subjects: NPT, LGB, DEI

Leading Teen and Young Adult Mental Health Treatment Provider Newport Healthcare Partners with Nonprofit To Write Love on Her Arms (TWLOHA) in Honor of Suicide Prevention Awareness Month


NASHVILLE, Tenn., Sept. 7, 2023 /PRNewswire/ -- The statistics are staggering: more than 20% of teens have seriously considered suicide. Thirteen percent of high school girls and more than 20% of LGBTQ+ teens have actually attempted it. And an increasing number of students report persistent feelings of sadness or hopelessness, including 57% of girls, 29% of boys, and 69% of LGBTQ+ students. Suicidal ideation and attempts are rising among young people, with the highest rate of attempts among young adults ages 18-25.

To amplify the conversation about suicide prevention and help reverse current trends, Newport Healthcare, a national network of evidence-based treatment programs for teens and young adults with primary mental health disorders, is partnering for the seventh year with To Write Love on Her Arms (TWLOHA), a nonprofit movement dedicated to presenting hope and finding help for people struggling with depression, addiction, self-injury, and suicide. The partnership announcement coincides with September's Suicide Prevention Awareness Month, which includes World Suicide Prevention Day (September 10) and Suicide Prevention Week (September 10?16).

"We are honored to be a long-time partner of TWLOHA and proud to support their mission of educating communities and connecting people to life-saving resources," said Joe Procopio, Chief Executive Officer of Newport Healthcare. "These statistics aren't just numbers, they're young lives, and we want to play an active part in stemming the tide of lives lost by helping families and individuals find hope and healing."

The Newport Healthcare and TWLOHA partnership includes raising awareness about suicide risk and prevention via cross-marketing efforts and a social media roundtable discussion. Newport further supports TWLOHA's mission with a matching gift donation and an employee and alumni team fundraising effort.

"Our alliance with Newport Healthcare is driving real change in suicide prevention, and they are a valued and critical partner helping to turn the tides from despair to hope," said Lindsay Kolsch, Co-Executive Director of TWLOHA. "This year, we have witnessed a record-breaking 50,000 recorded deaths by suicide in the U.S. and a drastic 72% increase in applications for our scholarships designed to address immediate mental health care needs. Our campaign, driven by powerful social media content, impactful events, and a comprehensive merchandise pack, strives to weave a robust network of support and represents a unique strategy against the devastating grip of suicide."

The theme for TWLOHA's 2023 Suicide Prevention Awareness Month campaign is "The World is Not Better Without You," which speaks directly to people experiencing loneliness and suicidal ideation. You can support TWLOHA by visiting their website at TWLOHA.com.

Newport Healthcare supports mental health care accessibility and affordability by offering free mental health resources and community support groups, expanding treatment services around the nation, and accepting most major insurances. For more information, visit NewportHealthcare.com.

About Newport Healthcare
Newport Healthcare is the nation's leading provider of evidence-based mental health treatment for youth, young adults, and families. Comprised of Newport Academy, Newport Institute, Center for Families, and PrairieCare, its full continuum of care includes psychiatric inpatient services, residential services, partial hospitalization programs (PHP), intensive outpatient programs (IOP), and virtual programs. Newport's family-centered, integrated approach fosters sustainable healing from a foundation of compassionate care, clinical expertise, and unconditional love. With a commitment to advocacy, Newport is creating a movement to shift our mental health culture from awareness to action, with the primary mission to empower lives and restore families.

About TWLOHA
To Write Love on Her Arms is a non-profit dedicated to presenting hope and finding help for people struggling with depression, addiction, self-injury, and suicide. TWLOHA exists to encourage, inform, inspire, and invest directly into treatment and recovery. Since its start in 2006, they have donated over $3.7 million directly into treatment and recovery and have answered over 210,000 emails from over 100 countries, and traveled more than 3.8 million miles to meet people face-to-face at nearly 3,000 events. Each month, they connect with 10 million people online through social media and their FIND HELP Tool fields 3,500 searches made by people seeking mental health resources.

CONTACT: [email protected] 

SOURCE Newport Healthcare


These press releases may also interest you

18 mai 2024
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

18 mai 2024
On Wednesday, May 15, Red Door Community hosted their annual Celebrating Women Working and Living with Cancer Luncheon at the Metropolitan Club in New York City. The event raised more than $300,000 while shining a light on the women who inspire us...

18 mai 2024
Product: Kalihim (Philippine Bread Roll) Issue: Food - Allergen - Egg Distribution: British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

18 mai 2024
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

18 mai 2024
Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRMtm System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEMtm Subcutaneous...

18 mai 2024
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...



News published on and distributed by: